Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Interpace Biosciences's OCF Margin % or its related term are showing as below:
STU:PF42'
s OCF Margin % Range Over the Past 10 Years
Min: -96.01 Med: -32.97 Max: 15.06
Current: 12.25
During the past 13 years, the highest OCF Margin % of Interpace Biosciences was 15.06%. The lowest was -96.01%. And the median was -32.97%.
STU:PF42's OCF Margin % is ranked better than 63.37% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.78
vs STU:PF42: 12.25
Interpace Biosciences OCF Margin % Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PF42 vs PRPO, ADVB, BIOQ: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Interpace Biosciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (STU:PF42) has a OCF Margin % of 1.07% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Interpace Biosciences and its competitors. According to the industry distribution chart, Interpace Biosciences ranks #74 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 36.6%.
Is Interpace Biosciences' OCF Margin % too high?
Interpace Biosciences' current OCF Margin % is 1.07%. The Medical Diagnostics & Research industry median OCF Margin % is 6.78. Interpace Biosciences' value of 1.07% is 84.2% below this industry median. Based on the distribution chart, Interpace Biosciences ranks #74 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Interpace Biosciences has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' OCF Margin % compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #74 out of 202 companies for OCF Margin %. This puts Interpace Biosciences in the upper half of its industry. The industry median OCF Margin % is 6.78. Interpace Biosciences' value of 1.07% is 84.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 6.78, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current OCF Margin % of 1.07% is 84.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Interpace Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current OCF Margin % is 1.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Interpace Biosciences (STU:PF42) has a current OCF Margin % of 1.07%. The stock's GF Value™ is €0.17, compared to a current price of €1.34 — trading 688.2% above its estimated fair value. The current OCF Margin % is 1.07% and 84.2% below the Medical Diagnostics & Research industry median of 6.78. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Interpace Biosciences (STU:PF42), the current OCF Margin % is 1.07% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (STU:PF42) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of €1.34 is trading 688.2% above its estimated GF Value™ of €0.17.
Key valuation signals for STU:PF42:
OCF Margin %: 1.07%
GF Value™: €0.17 vs. price of €1.34 (688.2% above fair value)
Industry Position: 84.2% below the Medical Diagnostics & Research median (#74 of 202)
No single metric tells the full story. See the STU:PF42 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for STU:PF42
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PF42 has been successfully added to your 
